On Sept. 9, 2020, Valneva announced the signing of a new contract, lasting up to three years, with the U.S. government Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO^® .

The new contract spans a total of three years (one base year, plus two option years) with a base-year value of $61 million.

IXIARO^® is the only JE vaccine approved by the U.S. Food and Drug Administration (FDA), having been developed through a cooperative research and development agreement with the Walter Reed Army Institute of Research. Valneva markets and distributes IXIARO^® directly to the U.S. military and U.S. private market.